Nanoparticles for Drug Delivery: How Nanomedicine Targets Cancer

Nanomaterials are classified into organic and inorganic categories based on composition. Inorganic nanomaterials lack carbon-hydrogen bonds and include metallic and metal oxide compounds such as nanoshells, quantum dots, iron oxide, gold, silica, and silver nanoparticles. Organic nanomaterials contain carbon-hydrogen bonds and include liposomes, polymeric nanoparticles, micelles, dendrimers, and lipid nanoparticles. Both categories can form self-assembled nanostructures through weak intermolecular interactions under specific conditions. This classification guides selection of appropriate nanocarriers for different therapeutic applications, balancing properties like biocompatibility, targeting capability, and drug loading efficiency.

Nanoparticles are classified into two main categories: by nature (organic nanoparticles including dendrimers, liposomes, and ferritin; inorganic nanoparticles including metal and metal oxide nanoparticles; and carbon-based nanoparticles including fullerenes, graphene, carbon nanotubes, and carbon nanocones) and by size/dimension (zero-dimensional nanoparticles with all dimensions below 100 nm, such as quantum dots; one-dimensional nanoparticles with two dimensions at nanoscale like nanowires and nanotubes; two-dimensional nanoparticles with one dimension at nanoscale like graphene layers; and three-dimensional nanoparticles with all dimensions above 100 nm).

Nanotechnology in pharmacy, known as nanobiotecnologia, involves the development of therapeutic systems at the nanoscale (1-1000 nm) that enable controlled drug delivery, improved targeting, and enhanced therapeutic efficacy. The five primary nanostructures used in pharmaceutical applications include: liposomes (amphiphilic lipid vesicles with concentric layers for encapsulating hydrophilic and hydrophobic compounds), polymeric nanoparticles (divided into capsules with distinguishable cores and spheres with homogeneous matrices), lipid-based nanoparticles (including nanostructured lipid carriers and solid lipid nanoparticles), dendrimers (symmetrical, branched molecules with internal cavities for drug encapsulation), and inorganic nanoparticles (offering low toxicity, controlled release, and imaging capabilities for targeted cancer therapy).

Nanomedicine for oncology employs various tools including nanoparticles for drug delivery, diagnostic systems for quick diagnosis, and therapeutic approaches combined with radiotherapy and immunotherapy. The armamentarium includes nano-scale delivery systems ranging from simple microemulsions to complex polymeric nanoparticles. Types of nanocarriers include microemulsions, liposomes, nanoemulsions, microclusters, multiple emulsions, microgels, biopolymer nanoparticles, polymeric nanospheres and nanocapsules, lipid nanocarriers (solid lipid nanoparticles), dendrimers, and metal nanoparticles (gold, silver). Advanced systems include mesoporous silicon nanoparticles for higher drug loading capacity.

Drug delivery nanoparticles are generally classified into three main categories based on their structure and composition. Nano shells consist of a core material surrounded by a thin shell, which can be metallic or polymeric, and can be engineered for stimulus-responsive behavior. Liposomes are bilayer vesicles composed of amphiphilic molecules with aqueous interiors and hydrophobic exteriors, capable of solubilizing both hydrophilic and hydrophobic drugs. Polymer nanoparticles offer diverse formulations including diffusion-controlled and erosion-controlled release systems. Each class provides distinct advantages for different therapeutic applications and release requirements.

Stimuli-responsive systems release drugs in response to environmental triggers: (1) pH-sensitive hydrogels - polymers containing acidic and basic groups swelling/shrinking depending on pH; (2) Temperature-responsive polymers - exhibit lower critical solution temperature (LCST), shrinking above LCST; (3) Enzyme-triggered systems - release activated by enzymes present at disease sites; (4) Glucose-responsive insulin delivery - glucose oxidase converts glucose to gluconic acid, lowering pH and triggering release. These intelligent systems provide self-regulated therapy maintaining therapeutic levels while minimizing systemic exposure. Applications include diabetes management, cancer therapy, and targeted release at pathological sites. The technology represents the frontier of personalized and precision medicine, enabling dynamic response to physiological changes.

Stimuli-responsive drug delivery systems use environmental triggers to control therapeutic release. Gatekeeper molecules (long-chain fatty acids or alcohols with precise melting points) block mesoporous silica pores when solid and release drugs when melted. Using capric acid (melting point 45°C) or tetradecanol (39°C), release can be triggered by temperature changes, enabling pulsatile delivery patterns. pH-sensitive block copolymers (like poly(ε-caprolactone) crystallizing below pH 4.5) bind positively charged drugs at physiological pH (7.4) and release them in acidic tumor microenvironments or cellular interiors. These smart systems provide inherent targeting without external activation. Combined with magnetic nanoparticles, these approaches enable multifunctional delivery where targeting, tracking, and release are integrated into single platforms.

Multiple stimuli-responsive drug delivery systems are developed: (1) pH-responsive systems where gates remain closed at physiological pH (7.4) but degrade in acidic tumor environments, enabling targeted cancer treatment; (2) magnetic-responsive systems using iron oxide nanoparticles within mesoporous silica, where external magnetic fields generate heat to trigger temperature-sensitive polymer conformation changes; (3) light-responsive systems with UV-sensitive polymers that break down under UV exposure; (4) ultrasound-responsive systems with ultrasound-sensitive polymer units. Evaluation involves in vitro cell viability testing and in vivo animal models.

Nanogels are nano-sized particles made of cross-linked polymer molecules that function like sponges, swelling when absorbing water and releasing their contents under specific stimuli such as pH or temperature changes; this tunable property allows scientists to design targeted drug delivery systems where therapeutic molecules are released only at desired locations, such as acidic tumor environments, making nanogels promising for treating cancer, autoimmune diseases, and neurodegenerative conditions.

Environmentally responsive drug delivery systems respond to specific physiological conditions. Colon-specific delivery uses pH-responsive polymers with azo bonds and carboxyl groups that remain non-ionized in the stomach but become charged in the colon, expanding pore size. Colonic microbiota enzymes further cleave these bonds for drug release. Glucose-sensitive systems use glucose oxidase enzymes that produce H+ ions when glucose is present, causing local pH drops that trigger polymer shrinkage and pore opening for drug release. Bio-shielding strategies coat particles with lipids, polymers (like PEG), carbohydrates, or proteins to prevent immune detection and improve circulation time.

Most nanomedicines remain far from clinical translation due to significant challenges: complexity of biological systems where nanoparticle internalization depends on size, shape, and surface functionality; biodistribution issues with most nanoparticles accumulating in liver and spleen (immune organs) rather than target tissues; and the need for systematic optimization of all parameters for each disease application. Surface modification is critical to avoid immune recognition (opsonization). Future directions include developing better predictive models for nanoparticle behavior, improving targeting specificity, and advancing manufacturing processes for consistent quality. The ultimate goal is achieving selective delivery to tumors while minimizing healthy tissue exposure—a 'magic bullet' approach for cancer treatment.

The FDA regulates nanomedicines under existing frameworks without separate nanotechnology-specific regulations. Regulatory decisions are based on three fundamental product attributes: quality, safety, and efficacy. The FDA considers nanotechnology as materials in the 1-100 nanometer range exhibiting unique phenomena enabling novel applications, with the definition extending beyond 100 nanometers up to a micron size if unique properties are present. FDA requires comprehensive characterization including identity, strength, quality, purity, potency, bioavailability, stability, manufacturing process, controls, and analytical procedures. Unlike small molecule drugs characterized by NMR, HPLC, and mass spectrometry, nanomedicines require additional techniques such as electron microscopy, dynamic light scattering, and static light scattering. Nanomedicines often contain surface coatings that significantly influence biological behavior, affecting pharmacokinetics, biodistribution, safety, and efficacy. Beyond size and coating, nanoparticle charge and shape significantly affect biological behavior. FDA has approved nanomedicines for over 40 years, with Doxil (doxorubicin encapsulated liposome) approved in 1995 as an early example. FDA submissions typically enter through IND (Investigational New Drug) applications for new drugs or IDE (Investigational Device Exemption) for devices. Nanomedicine preclinical development requires comprehensive physical-chemical characterization of nanoparticles including drug-loaded formulations. GMP-compliant nanomedicines require sterilization while maintaining product integrity. Gamma radiation can completely change metal nanoparticle structure, while steam sterilization is unsuitable for biologics. Interactions between nanoparticles, biologics, and storage/delivery vessels cause protein aggregation. Endotoxin measurement is a critical challenge for nanomedicines, where standard testing techniques face interference issues. EU clinical trials require facing national regulatory agencies for each country. The new EU Medical Device Regulation (MDR) creates significant challenges for nanomedicines, with many devices facing higher classification requiring more extensive clinical evidence and lifecycle updates. Individual device traceability is required rather than batch-level, increasing manufacturing costs.

Translating nanomedicine from laboratory to clinic requires addressing fundamental translational challenges. Biocompatibility demands that nanoparticles be biodegradable, non-immunogenic, and have established pharmacokinetic profiles. A critical consideration is the dilution effect: while animal studies use 10-fold dilution, human administration involves 3,500-fold dilution, dramatically affecting drug release kinetics. Many promising formulations fail because they work well in mice but fail in humans due to this difference. Comprehensive databases on composition, structure, and biological behavior are essential for accelerating development. The gap between preclinical success and clinical translation remains one of the greatest challenges in nanomedicine.

Despite high potential, precision nanomedicine faces several challenges: (1) Drug toxicity and immune response issues, (2) Tumor heterogeneity, (3) Regulatory challenges - cannot go to FDA for each individual patient treatment, requiring unified processes, (4) Big data issues from genetic information generation requiring analysis, interpretation, sharing, and storage, which creates privacy concerns and high costs. These challenges must be addressed for successful clinical translation of precision nanomedicine approaches.

Translating nanomedicine to clinical practice requires navigating FDA approval processes focused on safety (nano-toxicity) and efficacy. Nano periodic property patterns enable predicting toxicity through combinations of surface chemistry, size, shape, and architecture—critical for regulatory compliance. Size fundamentally determines excretion pathways, as demonstrated by real-time MRI studies showing kidney versus organ accumulation. Shape dramatically affects tissue penetration and flow properties, with cylindrical particles penetrating deeper than spheres. Surface chemistry modification offers nearly 1,000 options for tailoring properties. Current clinical candidates include VivaGel (Phase 3 antiviral), BIND (cancer therapy vector), and Abraxane (albumin-based). These examples illustrate how systematic parameter optimization transforms nanoparticles from laboratory curiosities into viable therapeutic platforms.